Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2008 16:54 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Conference Call Discussing Fourth Quarter and Year End 2007 Results

CAMBRIDGE, Mass., Feb. 7, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management...
February 04, 2008 08:03 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb. 4, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune today announced that the United States Adopted Names (USAN) Council,...
January 07, 2008 01:47 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Reviews 2007 Achievements and Announces 2008 Goals

CAMBRIDGE, Mass., Jan. 7, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced its 2008 product...
January 04, 2008 07:20 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity and MedImmune Initiate Phase 1b Trial of IPI-504 in Combination With Taxotere in Patients With Advanced Solid Tumor Cancers

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Jan. 4, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune announced that they have initiated a Phase 1b clinical trial of...
January 03, 2008 17:23 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Updated Presentation Time At the JPMorgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 3, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced an updated presentation...
December 19, 2007 12:02 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor's Potential Anti-Tumor Activity in Patients With Advanced Non-Small Cell Lung Cancer

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Dec. 19, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced that the companies have initiated the Phase 2...
December 17, 2007 10:45 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Present At the 2008 JPMorgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 17, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven H. Holtzman,...
November 20, 2007 10:05 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Present At Piper Jaffray Health Care Conference

CAMBRIDGE, Mass., Nov. 20, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven J. Kafka,...
November 13, 2007 08:17 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity and MedImmune Initiate Phase 2 Clinical Trial of IPI-504, a Novel Hsp90 Inhibitor, in Patients With Advanced Hormone-Refractory Prostate Cancer

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov. 13, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced that the companies have initiated a Phase 2...
November 12, 2007 07:25 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Hedgehog Pathway Inhibitor Agreement With AstraZeneca

Infinity Regains Full Rights to IPI-926 and Receives Opt-In Rights to AstraZeneca Hedgehog Pathway Inhibitor Programs Infinity Collaboration With MedImmune on Hsp90 Inhibitors Continues ...